These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 8213058)

  • 1. Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome.
    Lundh H; Nilsson O; Rosén I; Johansson S
    Acta Neurol Scand; 1993 Aug; 88(2):136-40. PubMed ID: 8213058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment for Lambert-Eaton myasthenic syndrome.
    Keogh M; Sedehizadeh S; Maddison P
    Cochrane Database Syst Rev; 2011 Feb; 2011(2):CD003279. PubMed ID: 21328260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.
    Wirtz PW; Titulaer MJ; Gerven JM; Verschuuren JJ
    Expert Rev Clin Immunol; 2010 Nov; 6(6):867-74. PubMed ID: 20979551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.
    Wirtz PW; Verschuuren JJ; van Dijk JG; de Kam ML; Schoemaker RC; van Hasselt JG; Titulaer MJ; Tjaden UR; den Hartigh J; van Gerven JM
    Clin Pharmacol Ther; 2009 Jul; 86(1):44-8. PubMed ID: 19357643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of 3,4-diaminopyridine on the time course of decay of compound muscle action potential augmentation in the Lambert-Eaton myasthenic syndrome.
    Maddison P; Newsom-Davis J; Mills KR
    Muscle Nerve; 1998 Sep; 21(9):1196-8. PubMed ID: 9703446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wide spectrum of symptomatic treatment in Lambert-Eaton myasthenic syndrome.
    Oh SJ; Kim DS; Kwon KH; Tseng A; Mussell H; Claussen GC
    Ann N Y Acad Sci; 1998 May; 841():827-31. PubMed ID: 9668337
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of Lambert-Eaton syndrome with 3,4- diaminopyridine and pyridostigmine].
    Yachachi Monfort A; Cortés Pastor F; de la Rubia Nieto A; Sánchez Garre MJ
    Farm Hosp; 2007; 31(4):254-6. PubMed ID: 18052623
    [No Abstract]   [Full Text] [Related]  

  • 8. [Successful treatment of a Lambert-Eaton myasthenic syndrome patient with 3,4-diaminopyridine].
    Matsushima M; Yaguchi H; Kishimoto R; Tsuji S; Yabe I; Sasaki H; Nakadate M; Shiraishi H; Motomura M
    Nihon Naika Gakkai Zasshi; 2007 Aug; 96(8):1709-11. PubMed ID: 17802724
    [No Abstract]   [Full Text] [Related]  

  • 9. 3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome.
    Molgó J; Guglielmi JM
    Pflugers Arch; 1996; 431(6 Suppl 2):R295-6. PubMed ID: 8739381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).
    Sanders DB
    Ann N Y Acad Sci; 1998 May; 841():811-6. PubMed ID: 9668334
    [No Abstract]   [Full Text] [Related]  

  • 11. 3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome.
    Lee MK; Sunwoo IN; Kim SM
    J Clin Neurosci; 2018 Apr; 50():194-198. PubMed ID: 29402568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment for Lambert-Eaton myasthenic syndrome.
    Maddison P; Newsom-Davis J
    Cochrane Database Syst Rev; 2003; (2):CD003279. PubMed ID: 12804456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.
    Quartel A; Turbeville S; Lounsbury D
    Curr Med Res Opin; 2010 Jun; 26(6):1363-75. PubMed ID: 20377318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS.
    Oh SJ; Claussen GG; Hatanaka Y; Morgan MB
    Muscle Nerve; 2009 Nov; 40(5):795-800. PubMed ID: 19722254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome.
    McEvoy KM; Windebank AJ; Daube JR; Low PA
    N Engl J Med; 1989 Dec; 321(23):1567-71. PubMed ID: 2555713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome.
    Maddison P; Newsom-Davis J; Mills KR
    J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):213-7. PubMed ID: 9703174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment in Lambert-Eaton myasthenic syndrome.
    Maddison P
    Ann N Y Acad Sci; 2012 Dec; 1275():78-84. PubMed ID: 23278581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lambert-Eaton myasthenic syndrome.
    Newsom-Davis J
    Rev Neurol (Paris); 2004 Feb; 160(2):177-80. PubMed ID: 15034474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term treatment of Lambert-Eaton syndrome by 3, 4 diaminopyridine].
    Jost WH; Mielke U; Forrett-Kaminsky MC; Schimrigk K
    Rev Neurol (Paris); 1992; 148(12):776-9. PubMed ID: 1303573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials.
    Zhang N; Hong D; Ouyang T; Meng W; Huang J; Li M; Hong T
    BMC Neurol; 2021 Sep; 21(1):371. PubMed ID: 34563155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.